<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00322205</url>
  </required_header>
  <id_info>
    <org_study_id>703463</org_study_id>
    <nct_id>NCT00322205</nct_id>
    <nct_alias>NCT00326755</nct_alias>
  </id_info>
  <brief_title>Bio-behavioral Lung Cancer Prevention Program</brief_title>
  <official_title>Bio-behavioral Lung Cancer Prevention Program</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute on Drug Abuse (NIDA)</source>
  <brief_summary>
    <textblock>
      The overall goal of this research is to increase our understanding of the role of individual
      genetic differences in response to bupropion treatment and the psychobiological mechanisms by
      which genetic and treatment factors interact in the smoking cessation process. The ultimate
      objective is to provide information necessary to match bupropion vs. behavioral counseling
      cessation treatment to those smokers with the greatest need and likelihood of benefit. This
      study is a double-blind randomized placebo-controlled clinical trial of bupropion HCL (brand
      name Zyban) in adult male and female smokers. The factorial design includes one treatment
      factor (bupropion 300 mg/day + counseling vs. placebo + counseling) and several subject
      factors (e.g. genotype, personality). Smoking history, psychological status will be assessed
      at baseline and blood will be drawn for genotyping. Bupropion or placebo will be delivered
      over a 10-week treatment period and subjects will be instructed to quit smoking after two
      weeks of medication (week 3 of treatment). All subjects will also receive a 7-week group
      behavioral smoking cessation treatment (over an 11 week period). This study may yield
      information that will help clinicians identify the most effective smoking cessation treatment
      for a particular patient, based on his/her background.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 1999</start_date>
  <completion_date>March 2002</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Continuous abstinence: measured at end of treatment and at 6- and 12- months after cessation.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Short-term quit rates using 7-day and 30-day point prevalence</measure>
  </secondary_outcome>
  <enrollment>555</enrollment>
  <condition>Smoking Cessation</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>zyban</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Eligible smokers will be those currently smoking at least 10 cigarettes a day.

        Exclusion Criteria:

        Exclusionary criteria are: planning a pregnancy, pregnancy, lactating, seizure disorder,
        history of head trauma or prior seizure, family history of a seizure disorder, brain (or
        CNS) tumor, history of or currently diagnosed with bulimia or anorexia nervosa, diabetes
        treated with oral hypoglycemics or insulin, excessive use of alcohol or alcoholism, current
        addiction to opiates, cocaine, or stimulants, use of other drugs containing bupropion
        (e.g., Wellbutrin, Wellbutrin SR), allergy to bupropion, currently taking particular
        medications (e.g., monoamine oxidase inhibitor, antipsychotics, antidepressants,
        theophylline, systemic steroids, over-the-counter stimulants and anorectics), recently
        taken a MAOI (less than 14 days) or a recent discontinuation of a benzodiazepine.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Caryn Lerman</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>State University of New York</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Lerman C, Jepson C, Wileyto EP, Epstein LH, Rukstalis M, Patterson F, Kaufmann V, Restine S, Hawk L, Niaura R, Berrettini W. Role of functional genetic variation in the dopamine D2 receptor (DRD2) in response to bupropion and nicotine replacement therapy for tobacco dependence: results of two randomized clinical trials. Neuropsychopharmacology. 2006 Jan;31(1):231-42.</citation>
    <PMID>16123753</PMID>
  </results_reference>
  <results_reference>
    <citation>Wileyto EP, Patterson F, Niaura R, Epstein LH, Brown RA, Audrain-McGovern J, Hawk LW Jr, Lerman C. Recurrent event analysis of lapse and recovery in a smoking cessation clinical trial using bupropion. Nicotine Tob Res. 2005 Apr;7(2):257-68.</citation>
    <PMID>16036283</PMID>
  </results_reference>
  <results_reference>
    <citation>Lerman C, Niaura R, Collins BN, Wileyto P, Audrain-McGovern J, Pinto A, Hawk L, Epstein LH. Effect of bupropion on depression symptoms in a smoking cessation clinical trial. Psychol Addict Behav. 2004 Dec;18(4):362-6.</citation>
    <PMID>15631608</PMID>
  </results_reference>
  <results_reference>
    <citation>Wileyto P, Patterson F, Niaura R, Epstein L, Brown R, Audrain-McGovern J, Hawk L, Lerman C, Patterson F. Do small lapses predict relapse to smoking behavior under bupropion treatment? Nicotine Tob Res. 2004 Apr;6(2):357-66.</citation>
    <PMID>15203809</PMID>
  </results_reference>
  <results_reference>
    <citation>Lerman C, Berrettini W, Pinto A, Patterson F, Crystal-Mansour S, Wileyto EP, Restine SL, Leonard DG, Shields PG, Epstein LH. Changes in food reward following smoking cessation: a pharmacogenetic investigation. Psychopharmacology (Berl). 2004 Aug;174(4):571-7. Epub 2004 Apr 27.</citation>
    <PMID>15138759</PMID>
  </results_reference>
  <results_reference>
    <citation>Collins BN, Wileyto EP, Patterson F, Rukstalis M, Audrain-McGovern J, Kaufmann V, Pinto A, Hawk L, Niaura R, Epstein LH, Lerman C. Gender differences in smoking cessation in a placebo-controlled trial of bupropion with behavioral counseling. Nicotine Tob Res. 2004 Feb;6(1):27-37.</citation>
    <PMID>14982685</PMID>
  </results_reference>
  <results_reference>
    <citation>Lerman C, Shields PG, Wileyto EP, Audrain J, Pinto A, Hawk L, Krishnan S, Niaura R, Epstein L. Pharmacogenetic investigation of smoking cessation treatment. Pharmacogenetics. 2002 Nov;12(8):627-34.</citation>
    <PMID>12439223</PMID>
  </results_reference>
  <results_reference>
    <citation>Lerman C, Roth D, Kaufmann V, Audrain J, Hawk L, Liu A, Niaura R, Epstein L. Mediating mechanisms for the impact of bupropion in smoking cessation treatment. Drug Alcohol Depend. 2002 Jul 1;67(2):219-23.</citation>
    <PMID>12095672</PMID>
  </results_reference>
  <verification_date>May 2006</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 4, 2006</study_first_submitted>
  <study_first_submitted_qc>May 4, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 5, 2006</study_first_posted>
  <last_update_submitted>January 10, 2017</last_update_submitted>
  <last_update_submitted_qc>January 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 11, 2017</last_update_posted>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

